Papanicolao (Pap ) Smear Examination:
Procedure, Purpose and Cervical Screening

A Pap smear examination, also called a Pap smear test or Pap test, is a screening procedure in which a small sample of cells is collected from the surface of the cervix and from the endocervical canal, transferred for laboratory preparation, stained, and examined under a microscope for abnormal changes.

The test is named after an American physician, Dr. George Papanicolaou, who developed the Pap smear. He was born in Greece and after completing his early medical training in 1913, he moved to the United States, where he spent decades working and developed the revolutionary Pap smear test for cervical cancer screening

Cervical cancer is unusual among cancers in that it is preceded by a long, detectable precancerous phase. The disease has a long pre-invasive phase of 10-15 years which makes it amenable to early detection by screening and treatment by relatively simpler modalities (WHO, 2014). Most abnormalities arise in the transformation zone, the area where the squamous epithelium of the outer cervix meets the columnar epithelium of the cervical canal. Cells shed from this zone can show changes years before invasive disease develops. A cervical cell sample taken from both the ectocervix and the endocervical canal gives the laboratory material from the area where abnormality is most likely to begin.

A Pap smear is a screening test, not a diagnostic one. It identifies women who need further evaluation. It does not confirm or rule out cancer on its own. A result reported as abnormal leads to further assessment, usually colposcopy with directed biopsy, and it is that assessment which produces a diagnosis.

Many national programmes now combine or replace cytology with high risk HPV testing, The natural history of cervical cancer is closely linked to persistent infection with high-risk Human Papillomavirus (HPV) types, which have been firmly established as the primary etiological agents in cervical carcinogenesis .HPV DNA testing is the most sensitive and reliable screening method and Pap smear remains valuable due to its high specificity,

The sample is collected by a qualified healthcare professional. In hospital and clinic settings this is usually a gynaecologist or a trained medical officer. In organised screening and outreach programmes, trained nurses, ANMs and other authorised health workers commonly perform collection under defined protocols. The prepared slide or vial is then evaluated by a cytotechnologist and reported by a pathologist.

Cervical cancer is one of the leading causes of women’s death worldwide, and the 2nd most common cancer among women in India after breast cancer. Considering its public health significance, it has always been a priority for global and national cancer control programs. Because the precancerous phase is long and treatable, the outcome for an individual woman depends heavily on whether she is screened at regular intervals rather than on any single test result. A one time Pap smear examination catches only what is present on that day. A screening programme repeated at the recommended interval is what actually reduces incidence and mortality.

Screening intervals vary by country, by guideline body and by whether HPV testing is used alongside cytology. Follow the protocol issued by the relevant national programme or professional body rather than a single global rule.

Broadly, most current guidance Recommend Screening by age as follows:

The sample goes for laboratory assessment

The labelled slide or vial is transported with its requisition form to the cytology laboratory. Turnaround time varies by facility and by country, commonly ranging from a few days to a few weeks.

Possible outcomes

• Negative for intraepithelial lesion or malignancy. No abnormal cells were identified. The woman continues routine cervical screening at the interval set by the applicable protocol.
• Unsatisfactory or inadequate. The laboratory could not assess the sample reliably, usually because of insufficient cells, obscuring blood or inflammation, or air drying artefact. A repeat sample is required, generally after a short interval.
• Abnormal cells identified. The report specifies the category of change. Management depends on that category alongside age, HPV status and screening history.
• Non cervical findings. Reactive changes, infection or organisms may be noted incidentally and managed on their own merits.

An abnormal result carries no benefit unless the woman receives it and action taken on it. Facilities should have a defined recall mechanism, a named person responsible for communicating results, and a documented referral route. In programme settings, loss to follow up is consistently a larger source of failure than sample collection error.

Where indicated, colposcopy allows magnified examination of the cervix and directed biopsy of suspicious areas. Histopathology on that biopsy, not the Pap smear, provides the diagnosis on which any treatment decision is based. Studies have proved that colposcopy has a higher diagnostic accuracy in detecting cervical premalignant and malignant lesions compared to the pap smear.

This page is intended as general clinical and product reference information for healthcare professionals and institutional buyers. It is not medical advice and does not replace the clinical judgement of a qualified practitioner or the instructions for use supplied with any device.